Skip to main content
Premium Trial:

Request an Annual Quote

Promega OncoMate MSI

Promega Corporation has launched the OncoMate MSI Dx Analysis System in the US. The in vitro diagnostic was cleared by the US Food and Drug Administration last month as an IVD medical device and gives oncologists and pathologists a new option to screen for Lynch syndrome in patients with colorectal cancer by determining microsatellite instability (MSI) status in their tumors.

Promega said it's underlying MSI technology has been in use for more than 15 years and is supported by over 140 peer-reviewed publications.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.